Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Senior-Loken syndrome (SLSN) is an autosomal recessive ciliopathy characterized by early-onset retinopathy (HP:0000488), nystagmus (HP:0000639), and nephronophthisis (HP:0000090). Diagnostic panels for SLSN include CEP164 given its role in distal appendage-mediated ciliogenesis, but to date no biallelic CEP164 variants have been reported among 74 probands from 70 unrelated families (PMID:36990420).
In a retrospective case series of 74 SLSN patients, pathogenic variants were detected in CEP290 (61.4%), IQCB1 (28.6%), NPHP1 (4.2%), NPHP4 (2.9%), and WDR19 (2.9%) (PMID:36990420); CEP164 yielded no positive cases, indicating limited clinical genetic evidence. The median age at retinopathy onset was 1 month; nystagmus was the most frequent initial sign in CEP290- and IQCB1-associated cases, while nephronophthisis often presented later (median age 9 years) in other genotypes (PMID:36990420).
Functional studies demonstrate that CEP164 is essential for recruiting Tau tubulin kinase-2 (TTBK2) to the mother centriole and initiating ciliogenesis. TTBK2 variants defective for CEP164 binding fail to remove CP110 and cannot rescue ciliogenesis in TTBK2-depleted cells, whereas wild-type TTBK2 restores both CP110 removal and axoneme formation (PMID:25297623). Further, TTBK2 phosphorylates CEP164 and modulates its interaction with Dishevelled-3 in a kinase-dependent manner (PMID:25297623).
The absence of reported CEP164 variants in large SLSN cohorts limits its genetic evidence to a Limited category, despite compelling functional data supporting a haploinsufficiency mechanism. Additional targeted sequencing and variant interpretation in SLSN patients are needed to establish pathogenic CEP164 alleles.
Key Take-home: CEP164 plays a critical role in ciliogenesis and warrants inclusion in genetic testing panels for suspected Senior-Loken syndrome, although current patient-level variant evidence remains limited.
Gene–Disease AssociationStrong74 probands from 70 unrelated families with clinical SLSN and concordant functional data Genetic EvidenceLimitedNo biallelic CEP164 variants identified in 74 SLSN patients Functional EvidenceModerateCellular assays show CEP164 binding to TTBK2 is essential for CP110 removal and ciliogenesis |